Clinical trial
A Randomized, Double-Blind, Placebo-Controlled Study of Single and Multiple Ascending Doses of ALT-801 in Healthy Overweight and Obese Volunteers
NCT04561245 is registered in ClinicalTrials.gov with Altimmune, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Double-Blind, Placebo-Controlled Study of Single and Multiple Ascending Doses of ALT-801 in Healthy Overweight and Obese Volunteers
- Lead sponsor
- Altimmune, Inc.
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- November 10, 2020
- Completion date
- October 29, 2021
- Enrollment
- 100 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
nonalcoholic steatohepatitis, obesity